Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
3.
J Alzheimers Dis ; 26(1): 181-6, 2011.
Article in English | MEDLINE | ID: mdl-21606570

ABSTRACT

Alzheimer's disease (AD) is a neurodegenerative process characterized by progressive neuronal degeneration, reduced levels of neurotransmitters, and altered forms of synaptic plasticity. In animal models of AD, amyloid-ß (Aß) and tau proteins are supposed to interfere with synaptic transmission. In the current study, we investigated the correlation between motor cortical plasticity, measured with 1 Hz repetitive transcranial magnetic stimulation (rTMS), and the levels of Aß1₋42, total tau (t-Tau), and phosphorylated tau (p-Tau) detected in cerebrospinal fluid (CSF) of AD patients. We found that the overall rTMS after effects were milder in AD patients in comparison with controls. In AD patients the amount of rTMS-induced inhibition correlated with CSF t-Tau, but not with Aß1₋42 CSF levels. Surprisingly, higher CSF t-Tau levels were associated to a stronger inhibition of the motor evoked potentials, implying that the expected effects of the 1 Hz rTMS protocol were more evident in patients with more pathological t-Tau CSF levels. These data could be interpreted as the consequence of CSF t-Tau mediated abnormal excitatory activity and could suggest that CSF t-Tau may impact mechanisms of cortical plasticity.


Subject(s)
Alzheimer Disease/cerebrospinal fluid , Alzheimer Disease/physiopathology , Cerebral Cortex/physiopathology , Neuronal Plasticity/physiology , tau Proteins/cerebrospinal fluid , Aged , Amyloid beta-Peptides/cerebrospinal fluid , Cerebral Cortex/pathology , Evoked Potentials, Motor/physiology , Female , Humans , Male , Mental Status Schedule , Middle Aged , Neuropsychological Tests , Peptide Fragments/cerebrospinal fluid , Transcranial Magnetic Stimulation/methods
4.
J Neurol ; 258(7): 1281-7, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21286740

ABSTRACT

Exercise therapy (ET) can be beneficial in disabled multiple sclerosis (MS) patients. Intermittent transcranial magnetic theta burst stimulation (iTBS) induces long-term excitability changes of the cerebral cortex and may ameliorate spasticity in MS. We investigated whether the combination of iTBS and a program of ET can improve motor disability in MS patients. In a double-blind, sham-controlled trial, 30 participants were randomized to three different interventions: iTBS plus ET, sham stimulation plus ET, and iTBS alone. Before and after 2 weeks of treatment, measures of spasticity through the modified Ashworth scale (MAS) and the 88 items Multiple Sclerosis Spasticity Score questionnaire (MSSS-88), fatigue through the Fatigue Severity Scale (FSS), daily living activities (ADL) through the Barthel index and health-related quality of life (HRQoL) through the 54 items Multiple Sclerosis Quality of life inventory (MSQoL-54) were collected. iTBS plus ET reduced MAS, MSSS-88, FSS scores, while in the Barthel index and MSQoL-54, physical composite scores were increased. iTBS alone caused a reduction of the MAS score, while none of the measured scales showed significant changes after sham iTBS plus ET. iTBS associated with ET is a promising tool for motor rehabilitation of MS patients.


Subject(s)
Exercise Therapy/methods , Multiple Sclerosis/rehabilitation , Multiple Sclerosis/therapy , Transcranial Magnetic Stimulation/methods , Adult , Disability Evaluation , Double-Blind Method , Evoked Potentials, Motor/physiology , Female , Humans , Male , Middle Aged , Multiple Sclerosis/physiopathology , Range of Motion, Articular/physiology , Severity of Illness Index , Statistics, Nonparametric , Time Factors
5.
Neuropsychopharmacology ; 36(3): 559-68, 2011 Feb.
Article in English | MEDLINE | ID: mdl-20944553

ABSTRACT

Cognitive dysfunction is of frequent observation in multiple sclerosis (MS). It is associated with gray matter pathology, brain atrophy, and altered connectivity, and recent evidence showed that acute inflammation can exacerbate mental deficits independently of the primary functional system involved. In this study, we measured cerebrospinal fluid (CSF) levels of amyloid-ß(1-42) and τ protein in MS and in clinically isolated syndrome patients, as both proteins have been associated with cognitive decline in Alzheimer's disease (AD). In AD, amyloid-ß(1-42) accumulates in the brain as insoluble extracellular plaques, possibly explaining why soluble amyloid-ß(1-42) is reduced in the CSF of these patients. In our sample of MS patients, amyloid-ß(1-42) levels were significantly lower in patients cognitively impaired (CI) and were inversely correlated with the number of Gadolinium-enhancing (Gd+) lesions at the magnetic resonance imaging (MRI). Positive correlations between amyloid-ß(1-42) levels and measures of attention and concentration were also found. Furthermore, abnormal neuroplasticity of the cerebral cortex, explored with θ burst stimulation (TBS), was observed in CI patients, and a positive correlation was found between amyloid-ß(1-42) CSF contents and the magnitude of long-term potentiation-like effects induced by TBS. No correlation was conversely found between τ protein concentrations and MRI findings, cognitive parameters, and TBS effects in these patients. Together, our results indicate that in MS, central inflammation is able to alter amyloid-ß metabolism by reducing its concentration in the CSF and leading to impairment of synaptic plasticity and cognitive function.


Subject(s)
Amyloid beta-Peptides/cerebrospinal fluid , Cerebral Cortex/physiopathology , Cognition Disorders/etiology , Multiple Sclerosis , Neuronal Plasticity/physiology , Peptide Fragments/cerebrospinal fluid , Adult , Amyloid beta-Peptides/pharmacology , Cerebral Cortex/pathology , Evoked Potentials, Motor/physiology , Female , Functional Laterality , Gadolinium , Humans , Long-Term Potentiation/drug effects , Magnetic Resonance Imaging/methods , Male , Middle Aged , Multiple Sclerosis/cerebrospinal fluid , Multiple Sclerosis/complications , Multiple Sclerosis/pathology , Muscle, Skeletal/innervation , Neurons/drug effects , Neurons/physiology , Neuropsychological Tests , Peptide Fragments/pharmacology , Statistics as Topic , Time Factors , Transcranial Magnetic Stimulation , Young Adult , tau Proteins/cerebrospinal fluid
6.
Clin Neurophysiol ; 122(3): 512-517, 2011 Mar.
Article in English | MEDLINE | ID: mdl-20864396

ABSTRACT

OBJECTIVES: To investigate the inter-hemispheric connections between the dorsal premotor cortex (dPM) and contralateral primary motor cortex (M1) in schizophrenia. METHODS: Sixteen medicated, nine unmedicated schizophrenia patients and 20 healthy age-matched subjects were studied by twin-coil Transcranial Magnetic Stimulation. To activate distinct facilitatory and inhibitory transcallosal pathways between dPM and the contralateral M1, the intensity of dPM stimulation was adjusted to be either suprathreshold (110% of resting motor threshold) or subthreshold (80% of active motor threshold). Interstimulus intervals between conditioning stimulus and test stimulus were 6, 8 and 15 ms. RESULTS: Schizophrenia patients had comparable efficacy of the inhibitory pathway. On the other hand, medicated patients showed less facilitation of contralateral M1 following dPM stimulation at 80% of active motor threshold, at interstimulus interval=8 ms. The individual amount of facilitation induced by dPM conditioning at 80% of active motor threshold at interstimulus interval=8 ms correlated negatively with negative symptoms. CONCLUSIONS: Inter-hemispheric facilitatory dPM-M1 connectivity is selectively altered in schizophrenia. SIGNIFICANCE: This study produced evidence that dPM-M1 connectivity is dysfunctional and that correlates with negative symptoms. These results converge with previous studies which strongly hypothesize that inter- and intra-hemispheric connectivity disturbances may play a major role in schizophrenia.


Subject(s)
Corpus Callosum/physiopathology , Functional Laterality/physiology , Schizophrenia/physiopathology , Adult , Antipsychotic Agents/pharmacology , Data Interpretation, Statistical , Electromyography , Evoked Potentials, Motor/physiology , Female , Humans , Male , Middle Aged , Motor Cortex/physiopathology , Neural Pathways/physiology , Schizophrenia/drug therapy , Transcranial Magnetic Stimulation , Young Adult
7.
Clin Neurophysiol ; 122(4): 703-7, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21075682

ABSTRACT

OBJECTIVE: Mechanisms of synaptic plasticity like long term depression (LTD) are altered in experimental models of Alzheimer's disease (AD). LTD-like plasticity mechanisms has not been yet fully investigated in AD patients. METHODS: Here we studied the effects of low frequency (1 Hz) repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex in a group of patients with a diagnosis of probable AD, compared to healthy age-matched controls (HS). Moreover, we tested the effects of a single dose of orally administered L-dopa, one of the key neurotransmitters in modulating synaptic plasticity mechanisms, on rTMS induced plasticity. RESULTS: We found that in AD patients the 1 Hz rTMS protocol did not induce the expected inhibitory effect, while a long lasting inhibition of MEP was observed in HS. In addition, L-dopa induced a clear form of reversal of the direction of plasticity in HS that was not evident in AD. CONCLUSIONS: Dopamine modulation of LTD-like plasticity is impaired when tested in AD patients. SIGNIFICANCE: These findings provide evidence of possible dysfunction of dopaminergic transmission in AD patients.


Subject(s)
Alzheimer Disease/physiopathology , Dopamine/physiology , Neuronal Plasticity/physiology , Aged , Alzheimer Disease/psychology , Cerebral Cortex/physiopathology , Data Interpretation, Statistical , Dopamine Agents/pharmacology , Electroencephalography , Evoked Potentials, Motor/drug effects , Evoked Potentials, Motor/physiology , Female , Humans , Levodopa/pharmacology , Long-Term Potentiation/physiology , Male , Motor Cortex/physiology , Neuropsychological Tests , Synapses/physiology , Transcranial Magnetic Stimulation
8.
Mult Scler ; 16(11): 1308-16, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20702503

ABSTRACT

BACKGROUND: Patients with multiple sclerosis may present altered patterns of connectivity between the two brain hemispheres. To date, only transcallosal connectivity between the two primary motor cortices (M1) has been investigated functionally in patients with multiple sclerosis. OBJECTIVES: The aim of this study was to investigate whether connectivity between the dorsal premotor cortex and the contralateral M1 was altered in patients with multiple sclerosis, and to see whether clinical progression is accompanied by exacerbated dorsal premotor cortex-M1 disconnectivity. METHODS: A twin-coil transcranial magnetic stimulation approach was used to investigate both excitatory and inhibitory interhemispheric connections between the left dorsal premotor cortex and the contralateral M1 in 18 multiple sclerosis patients without disability, in 18 multiple sclerosis patients with advanced disease and in 12 age-matched healthy subjects. To activate distinct inhibitory and facilitatory transcallosal pathways, the intensity of dorsal premotor cortex stimulation was adjusted to be either suprathreshold (110% of resting motor threshold) or subthreshold (80% of active motor threshold). RESULTS: Our sample of patients with multiple sclerosis showed altered patterns of interhemispheric dorsal premotor cortex-M1 functional connectivity even in the absence of clinical deficits. Facilitatory connections originating from dorsal premotor cortex were reduced in multiple sclerosis patients with or without disability, while inhibitory dorsal premotor cortex-M1 connections were altered only in disabled patients. CONCLUSIONS: The current study demonstrates that functional excitatory connectivity originating from non-primary motor areas is compromised in multiple sclerosis patients even in the absence of clinical disability. Clinical disease progression leads to an impairment of both excitatory and inhibitory transcallosal connections.


Subject(s)
Brain/physiopathology , Multiple Sclerosis/physiopathology , Neural Pathways/physiopathology , Adult , Brain/pathology , Brain Mapping , Female , Functional Laterality/physiology , Humans , Image Interpretation, Computer-Assisted , Male , Middle Aged , Multiple Sclerosis/pathology , Neural Pathways/pathology , Transcranial Magnetic Stimulation
9.
J Pain ; 11(5): 436-42, 2010 May.
Article in English | MEDLINE | ID: mdl-20018567

ABSTRACT

UNLABELLED: Neuropathic pain in patients with MS is frequent and is associated with a great interference with daily life activities. In the present study, we investigated whether anodal transcranial direct current stimulation (tDCS) may be effective in reducing central chronic pain in MS patients. Patients received sham tDCS or real tDCS in a 5-day period of treatment in a randomized, double blind, sham-controlled study. Pain was measured using visual analog scale (VAS) for pain and the short form McGill questionnaire (SF-MPQ). Quality of life was measured using the Multiple Sclerosis Quality of Life-54 scale (MSQoL-54). Depressive symptoms and anxiety were also evaluated as confounding factors using the Beck Depression Inventory (BDI) and VAS for anxiety. Evaluations were performed at baseline, immediately after the end of treatment, and once a week during a 3-week follow-up period. Following anodal but not sham tDCS over the motor cortex, there was a significant pain improvement as assessed by VAS for pain and McGill questionnaire, and of overall quality of life. No depression or anxiety changes were observed. Our results show that anodal tDCS is able to reduce pain-scale scores in MS patients with central chronic pain and that this effect outlasts the period of stimulation, leading to long-lasting clinical effects. PERSPECTIVE: This article presents a new, noninvasive therapeutic approach to chronic, central neuropathic pain in multiple sclerosis, poorly responsive to current conventional medications. tDCS is known to cause long-lasting changes of neuronal excitability at the site of stimulation and in the connected areas in healthy subjects. This led us to hypothesize that pain decrease may be the result of functional plastic changes in brain structures involved in the pathogenesis of chronic neuropathic pain.


Subject(s)
Electric Stimulation Therapy/methods , Multiple Sclerosis/therapy , Neuralgia/therapy , Adult , Aged , Anxiety/therapy , Chronic Disease , Depression/therapy , Double-Blind Method , Female , Follow-Up Studies , Humans , Male , Middle Aged , Pain Measurement , Psychiatric Status Rating Scales , Quality of Life , Surveys and Questionnaires , Time Factors , Treatment Outcome , Young Adult
10.
Neurol Sci ; 30(6): 531-4, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19768368

ABSTRACT

The endocannabinoid system (ECS) is involved in the pathophysiology of multiple sclerosis (MS), and relief from pain and spasticity has been reported in MS patients self-medicating with marijuana. A cannabis-based medication containing Delta(9)-tetrahydrocannabinol and cannabidiol (Sativex) has been approved in some countries for the treatment of MS-associated pain. The effects of this pharmaceutical preparation on other clinically relevant aspects of MS pathophysiology, however, are still unclear. In 20 MS patients, we measured the effects of Sativex on clinically measured spasticity and on neurophysiological and laboratory parameters that correlate with spasticity severity or with the modulation of the ECS. Sativex failed to affect spasticity and stretch reflex excitability. This compound also failed to affect the synthesis and the degradation of the endocannabinoid anandamide, as well as the expression of both CB1 and CB2 cannabinoid receptors in various subpopulations of peripheral lymphocytes.


Subject(s)
Cannabinoids/therapeutic use , Multiple Sclerosis/drug therapy , Plant Extracts/therapeutic use , Adult , Arachidonic Acids/metabolism , Cannabidiol , Dronabinol , Drug Combinations , Endocannabinoids , Female , Humans , Lymphocytes/drug effects , Lymphocytes/metabolism , Male , Middle Aged , Multiple Sclerosis/complications , Multiple Sclerosis/physiopathology , Muscle Spasticity/drug therapy , Muscle Spasticity/etiology , Muscle Spasticity/physiopathology , Pain/drug therapy , Pain/etiology , Pain/physiopathology , Polyunsaturated Alkamides/metabolism , Receptor, Cannabinoid, CB1/metabolism , Receptor, Cannabinoid, CB2/metabolism , Reflex, Stretch/drug effects , Treatment Outcome , Young Adult
11.
Neuropsychopharmacology ; 34(10): 2323-8, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19516251

ABSTRACT

In Alzheimer's disease (AD) patients dysfunction of cholinergic neurons is considered a typical hallmark, leading to a rationale for the pharmacological treatment in use based on drugs that enhance acetylcholine neurotransmission. However, besides altered acetylcholine transmission, other neurotransmitter systems are involved in cognitive dysfunction leading to dementia. Among others, dopamine seems to be particularly involved in the regulation of cognitive processes, also having functional relationship with acetylcholine. To test whether cholinergic dysfunction can be modified by dopamine, we used short latency afferent inhibition (SLAI) as a neurophysiological tool. First, we tested the function of the cholinergic system in AD patients and in healthy subjects. Then, we tested whether a single L-dopa challenge was able to interfere with this system in both groups. We observed that SLAI was reduced in AD patients, and preserved in normal subjects. L-dopa administration was able to restore SLAI modification only in AD, having no effect in healthy subjects. We conclude that dopamine can modify SLAI in AD, thus confirming the relationship between acetylcholine and dopamine systems. Moreover, it is suggested that together with cholinergic, dopaminergic system alteration is likely to occur in AD, also. These alterations might be responsible, at least in part, for the progressive cognitive decline observed in AD patients.


Subject(s)
Acetylcholine/metabolism , Alzheimer Disease/pathology , Cerebral Cortex/drug effects , Dopamine Agents , Dopamine/pharmacology , Neural Inhibition/physiology , Aged , Alzheimer Disease/drug therapy , Cerebral Cortex/metabolism , Cerebral Cortex/physiopathology , Dopamine/therapeutic use , Dopamine Agents/pharmacology , Dopamine Agents/therapeutic use , Electric Stimulation/methods , Humans , Levodopa/therapeutic use , Neural Inhibition/drug effects , Neuropsychological Tests , Reaction Time/drug effects , Reaction Time/physiology , Statistics as Topic , Time Factors , Transcranial Magnetic Stimulation/methods
12.
Brain Stimul ; 2(4): 229-33, 2009 Oct.
Article in English | MEDLINE | ID: mdl-20633421

ABSTRACT

BACKGROUND: In animal models, the cannabinoid system has been convincingly implicated in the regulation of long-lasting synaptic plasticity. Both long-term potentiation (LTP) and depression (LTD) phenomena can be induced in the human motor cortex by transcranial magnetic theta burst stimulation (TBS). OBJECTIVE/HYPOTHESIS: Here, we explored the potential involvement of the cannabinoid system in TBS-induced synaptic plasticity in humans. METHODS: We tested the effects of a cannabis-based preparation (Sativex) on continuous TBS (cTBS) and intermittent TBS (iTBS) protocols in subjects with multiple sclerosis. RESULTS: We observed a shift in the polarity of synaptic plasticity induced by cTBS. In these subjects, in fact, cTBS induced the expected inhibition of motor-evoked potentials (MEPs) before Sativex exposure, whereas it caused a persisting enhancement of MEP amplitude 4 weeks after. The LTP-like phenomenon induced by iTBS was conversely unaffected by Sativex. CONCLUSIONS: Our results indicate that cannabis ingredients have metaplastic effects on the motor cortex, and strongly suggest that the cannabinoid system is involved in the modulation of synaptic plasticity not only in rodents but also in humans.


Subject(s)
Cannabinoids , Neuronal Plasticity , Plant Extracts , Theta Rhythm , Transcranial Magnetic Stimulation/methods , Adult , Animals , Cannabidiol , Cannabinoids/pharmacology , Cannabinoids/therapeutic use , Dronabinol , Drug Combinations , Evoked Potentials, Motor/drug effects , Evoked Potentials, Motor/physiology , Female , Humans , Long-Term Potentiation/drug effects , Long-Term Potentiation/physiology , Long-Term Synaptic Depression/drug effects , Long-Term Synaptic Depression/physiology , Male , Middle Aged , Motor Cortex/drug effects , Motor Cortex/physiology , Multiple Sclerosis/drug therapy , Multiple Sclerosis/physiopathology , Neuronal Plasticity/drug effects , Neuronal Plasticity/physiology , Plant Extracts/pharmacology , Plant Extracts/therapeutic use
13.
Clin Neurophysiol ; 119(11): 2559-69, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18824403

ABSTRACT

OBJECTIVE: The cerebellum takes part in several motor functions through its influence on the motor cortex (M1). Here, we applied the theta burst stimulation (TBS) protocol, a novel form of repetitive Transcranial Magnetic Stimulation (rTMS) over the lateral cerebellum. The aim of this study was to test whether TBS of the lateral cerebellum could be able to modulate the excitability of the contralateral M1 in healthy subjects. METHODS: Motor-evoked potentials (MEPs) amplitude, short intracortical inhibition (SICI), long intracortical inhibition (LICI) and short intracortical facilitation (SICF) were tested in the M1 before and after cerebellar continuous TBS (cTBS) or intermittent TBS (iTBS). RESULTS: We found that cTBS induced a reduction of SICI and an increase of LICI. On the other hand, cerebellar iTBS reduced LICI. MEPs amplitude also differently vary following cerebellar stimulation with cTBS or iTBS, resulting in a decrease by the former and an increase by the latter. CONCLUSIONS: Although the interpretation of these data remains highly speculative, these findings reveal that the cerebellar cortex undergoes bidirectional plastic changes that modulate different intracortical circuits within the contralateral primary motor cortex. SIGNIFICANCE: Long-lasting modifications of these pathways could be useful to treat various pathological conditions characterized by an altered cortical excitability.


Subject(s)
Cerebellum/radiation effects , Electric Stimulation/methods , Evoked Potentials, Motor/physiology , Motor Cortex/physiology , Theta Rhythm , Adult , Analysis of Variance , Cerebellum/physiology , Differential Threshold/physiology , Electromyography/methods , Female , Functional Laterality , Hand/innervation , Humans , Male , Neck Muscles/innervation , Neural Inhibition/physiology , Neural Inhibition/radiation effects , Psychomotor Performance , Time Factors , Transcranial Magnetic Stimulation , Young Adult
14.
Biol Psychiatry ; 64(9): 815-9, 2008 Nov 01.
Article in English | MEDLINE | ID: mdl-18632089

ABSTRACT

BACKGROUND: Recent advances have highlighted the hypothesis of schizophrenia as a disorder causing defective connectivity among distinct cortical regions. Neurophysiological evidence supporting this hypothesis, however, is still lacking. METHODS: In the present study, we used a novel twin-coil transcranial magnetic stimulation (tcTMS) approach to investigate ipsilateral parieto-motor connectivity in 20 schizophrenic patients (14 medicated, 6 unmedicated) and in 15 healthy age-matched volunteers. RESULTS: In healthy subjects, a conditioning TMS pulse applied over the ipsilateral posterior parietal cortex (PPC) at 90% of resting motor threshold (RMT) intensity was able to increase the excitability of the hand area of the right primary motor cortex, with peaks at interstimulus intervals (ISIs) of 4 and 15 msec. This paradigm of stimulation failed to reveal any facilitatory parieto-motor interaction in medicated and unmedicated schizophrenic patients. The between-group difference in paired-pulse facilitation was not ISI-specific. In following analyses, we found that the effects across ISIs induced by PPC conditioning at 90% RMT correlated with the Global Assessment Functioning score and with the negative subscale of the Positive and Negative Syndrome Scale, showing that patients with a better global functioning and lower negative symptoms had less impaired connectivity. Moreover the same parameter correlated with illness duration. CONCLUSIONS: Parieto-motor connectivity is impaired in schizophrenia. Cortico-cortical disconnection might be a core feature of schizophrenia.


Subject(s)
Evoked Potentials, Motor/physiology , Motor Cortex/physiopathology , Parietal Lobe/physiopathology , Schizophrenia/pathology , Transcranial Magnetic Stimulation , Adult , Brain Mapping , Case-Control Studies , Electric Stimulation/methods , Electromyography/methods , Female , Humans , Male , Motor Cortex/pathology , Neural Pathways/physiopathology , Parietal Lobe/pathology , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...